Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor

BACKGROUND: Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purification, characterization, crystallization, and high-resolution diffraction are all needed for rapid, iterative structure determination. Janus kinases ar...

詳細記述

保存先:
書誌詳細
主要な著者: Argiriadi, Maria A, Goedken, Eric R, Banach, David, Borhani, David W, Burchat, Andrew, Dixon, Richard W, Marcotte, Doug, Overmeyer, Gary, Pivorunas, Valerie, Sadhukhan, Ramkrishna, Sousa, Silvino, Moore, Nigel St John, Tomlinson, Medha, Voss, Jeffrey, Wang, Lu, Wishart, Neil, Woller, Kevin, Talanian, Robert V
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2012
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3478977/
https://ncbi.nlm.nih.gov/pubmed/22995073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6807-12-22
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料